Arcus Biosciences, Inc.RCUSNYSE

Revenue (LTM)

$247M

-4.3% YoY

Net Income (LTM)

$-353M

-24.7% YoY

Free Cash Flow

$-484M

Revenue CAGR (5Y)

+25.9%

—Marginsstable

FCF($0.5B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	383	112↓70.8%	117↑4.5%	258↑120.5%	247↓4.3%
Gross Profit	383	112↓70.8%	117↑4.5%	258↑120.5%	237↓8.1%
Operating Income	54	-280↓618.5%	-340↓21.4%	-330↑2.9%	-386↓17.0%
Net Income	53	-267↓603.8%	-307↓15.0%	-283↑7.8%	-353↓24.7%
EBITDA	59	-258↓537.3%	-291↓12.8%	-269↑7.6%	-335↓24.5%
EPS Diluted	0.71	-3.71↓622.5%	-4.15↓11.9%	-3.14↑24.3%	-3.29↓4.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	148	206↑39.3%	127↓38.3%	150↑18.1%	222↑48.0%
Total Current Assets	1,262	1,066↓15.5%	831↓22.0%	1,016↑22.3%	1,007↓0.9%
Total Assets	1,592	1,345↓15.5%	1,095↓18.6%	1,150↑5.0%	1,139↓1.0%
Total Current Liabilities	166	193↑16.2%	184↓4.7%	226↑22.8%	231↑2.2%
Total Liabilities	750	688↓8.3%	633↓8.0%	665↑5.1%	508↓23.6%
Total Equity	841	657↓21.9%	462↓29.7%	485↑5.0%	631↑30.1%
Total Debt	122	120↓1.6%	11↓90.8%	60↑445.5%	99↑65.0%
Net Debt	-26	-86↓231.7%	-116↓34.9%	-90↑22.4%	-123↓36.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-256	438↑271.0%	-306↓169.9%	-170↑44.4%	-482↓183.5%
Capital Expenditure	-26	-6↑77.0%	-24↓300.0%	-6↑75.0%	-2↑66.7%
Free Cash Flow	-282	432↑253.1%	-330↓176.4%	-176↑46.7%	-484↓175.0%
Stock-Based Comp	55	0	73	76↑4.1%	60↓21.1%
Net Change in Cash	-23	58↑355.9%	-79↓236.0%	23↑129.1%	72↑213.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance